Treatment with glucagon-like Peptide-1 agonist exendin-4 in a patient with hypothalamic obesity secondary to intracranial tumor.

Simmons JH, Shoemaker AH, Roth CL

Hormone research in paediatrics20 Jul 2012Cited by 27 (Europe PMC)

PMID22831918DOI10.1159/000339469PepBankPUB-22831918

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

01HumanNot a test of Exenatide (exendin-4) aloneCase report or seriesEfficacy outcome
In a patient with hypothalamic obesity receiving chemoradiotherapy and exenatide, weight fell by 29 kg after 2.5 years.
In plain wordsIn a patient with hypothalamic obesity receiving chemoradiotherapy and exenatide, weight fell by 29 kg after 2.5 years.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight during treatment
Study
n = 1
Outcome group
Body weight · Metabolic and weight
Measurements
Weight loss
29 kg
treatment regimen
Source sentences
Summary
Exenatide resulted in a 29-kg weight loss (BMI reduction from 37.1 to 29.1) after 2.5 years of treatment; significant weight gain occurred shortly after exenatide was discontinued.
2 context sentences(design, population, supporting numbers)
Summary · context
We report the case of a 17-year-old patient with obesity resulting from a hypothalamic germ cell tumor.
Summary · context
He was treated by chemoradiotherapy and exenatide at a dose of 5 µg subcutaneously twice daily.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2283191801
02HumanNot a test of Exenatide (exendin-4) aloneCase report or seriesEfficacy outcome
In a patient with hypothalamic obesity receiving chemoradiotherapy and exenatide, BMI fell from 37.1 to 29.1.
In plain wordsIn a patient receiving chemoradiotherapy and exenatide, body mass index fell from 37.1 to 29.1.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBMI during treatment
Study
n = 1
Outcome group
Body weight · Metabolic and weight
Measurements
BMI
37.1 kg/m2
before treatment
BMI
29.1 kg/m2
after treatment
Source sentences
Summary
Exenatide resulted in a 29-kg weight loss (BMI reduction from 37.1 to 29.1) after 2.5 years of treatment; significant weight gain occurred shortly after exenatide was discontinued.
2 context sentences(design, population, supporting numbers)
Summary · context
We report the case of a 17-year-old patient with obesity resulting from a hypothalamic germ cell tumor.
Summary · context
He was treated by chemoradiotherapy and exenatide at a dose of 5 µg subcutaneously twice daily.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2283191802
03HumanNot a test of Exenatide (exendin-4) aloneCase report or seriesEfficacy outcome
In a patient with hypothalamic obesity treated with chemoradiotherapy and exenatide, significant weight gain followed exenatide discontinuation.
In plain wordsIn a patient treated with chemoradiotherapy and exenatide, weight increased significantly soon after exenatide stopped.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseWeight after exenatide discontinuation
Study
n = 1
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Exenatide resulted in a 29-kg weight loss (BMI reduction from 37.1 to 29.1) after 2.5 years of treatment; significant weight gain occurred shortly after exenatide was discontinued.
2 context sentences(design, population, supporting numbers)
Summary · context
We report the case of a 17-year-old patient with obesity resulting from a hypothalamic germ cell tumor.
Summary · context
He was treated by chemoradiotherapy and exenatide at a dose of 5 µg subcutaneously twice daily.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2283191803

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.